Antiretroviral nanoparticles: An extended drug delivery modality

Christopher J. Destache, Michael Goede, Todd Belgum

Research output: Contribution to journalArticle

Abstract

The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalTherapeutic Delivery
Volume1
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Nanoparticles
Pharmacy Schools
Health Occupations
Pharmaceutical Preparations
HIV-1

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Antiretroviral nanoparticles : An extended drug delivery modality. / Destache, Christopher J.; Goede, Michael; Belgum, Todd.

In: Therapeutic Delivery, Vol. 1, No. 3, 09.2010, p. 383-386.

Research output: Contribution to journalArticle

Destache, Christopher J. ; Goede, Michael ; Belgum, Todd. / Antiretroviral nanoparticles : An extended drug delivery modality. In: Therapeutic Delivery. 2010 ; Vol. 1, No. 3. pp. 383-386.
@article{dd37d74dfe164845b2160a2f25fdab12,
title = "Antiretroviral nanoparticles: An extended drug delivery modality",
abstract = "The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.",
author = "Destache, {Christopher J.} and Michael Goede and Todd Belgum",
year = "2010",
month = "9",
doi = "10.4155/tde.10.42",
language = "English",
volume = "1",
pages = "383--386",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "3",

}

TY - JOUR

T1 - Antiretroviral nanoparticles

T2 - An extended drug delivery modality

AU - Destache, Christopher J.

AU - Goede, Michael

AU - Belgum, Todd

PY - 2010/9

Y1 - 2010/9

N2 - The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

AB - The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=79954505080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954505080&partnerID=8YFLogxK

U2 - 10.4155/tde.10.42

DO - 10.4155/tde.10.42

M3 - Article

C2 - 22816141

AN - SCOPUS:79954505080

VL - 1

SP - 383

EP - 386

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 3

ER -